Clinical Trials on BARD1 Gene Mutation in Portugal
Total 15 results
-
QED Therapeutics, Inc.Helsinn Healthcare SATerminatedFGFR2 Gene Mutation | Advanced CholangiocarcinomaKorea, Republic of, United States, Belgium, Spain, Taiwan, China, United Kingdom, France, Canada, Germany, Thailand, Italy, Portugal, Australia, Puerto Rico
-
Rhythm Pharmaceuticals, Inc.CompletedPro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene MutationsUnited States, Israel, Canada, Germany, Greece, Italy, Portugal
-
Ana Catarina Reis de CarvalhoUniversity of LisbonUnknown
-
Pierre Fabre MedicamentRecruitingMetastatic Melanoma | Melanoma (Skin) | BRAF V600 MutationPortugal
-
Tesaro, Inc.European Organisation for Research and Treatment of Cancer - EORTC; Breast... and other collaboratorsTerminatedOvarian Neoplasms | BRCA1 Gene Mutation | BRCA2 Gene Mutation | Neoplasms, Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Carcinoma of BreastUnited States, Spain, Belgium, Israel, United Kingdom, Italy, Poland, Canada, Hungary, Netherlands, France, Portugal, Greece, Iceland
-
Taiho Oncology, Inc.Active, not recruitingAdvanced Cholangiocarcinoma | FGFR2 Gene RearrangementsUnited States, Spain, United Kingdom, Australia, Taiwan, Italy, France, Korea, Republic of, Belgium, Japan, Thailand, Germany, Brazil, Peru, Portugal, Argentina, Hong Kong, Mexico, Netherlands, Poland
-
PfizerCompletedTransthyretin Amyloidosis | Transthyretin Gene MutationsUnited States, France, Spain, Taiwan, Israel, Korea, Republic of, Denmark, Canada, Netherlands, Japan, Sweden, Brazil, Mexico, Argentina, Portugal, Belgium, Bulgaria, Cyprus, Germany, Italy, Malaysia, Romania, Saudi Arabia, Turkey, United...
-
University College London HospitalsCompletedBreast Cancer | Hereditary Breast/Ovarian Cancer (brca1, brca2) | brca1 Mutation Carrier | brca2 Mutation CarrierAustralia, Israel, United Kingdom, Spain, Sweden, Portugal
-
AstraZenecaCompletedCaucasian Patients With EGFR Mutation Positive Advanced NSCLCBulgaria, Italy, Poland, Spain, Turkey, United Kingdom, Romania, Norway, Hungary, Portugal, Greece, Switzerland, France
-
Taiho Oncology, Inc.RecruitingAdvanced Cholangiocarcinoma | FGFR2 Fusions | Gene RearrangementUnited States, Korea, Republic of, Spain, Japan, Portugal, Italy, China, Argentina, Brazil, Poland, Australia
-
BayerRecruitingAdvanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 MutationHong Kong, United States, Taiwan, Spain, Belgium, China, Japan, France, Korea, Republic of, Singapore, Poland, Israel, Italy, Netherlands, Portugal, Brazil
-
Novartis PharmaceuticalsTerminatedMyelofibrosis With High Molecular Risk MutationsBelgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
-
Astellas Pharma Global Development, Inc.CompletedAcute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) MutationTaiwan, Poland, Serbia, United States, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Portugal, Romania, Spain, Sweden, United Kingdom
-
Novartis PharmaceuticalsRecruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationItaly, Spain, United States, France, Thailand, Malaysia, China, Germany, India, Turkey, Belgium, Argentina, Bulgaria, Netherlands, Hungary, Greece, Portugal, Austria, Singapore, Brazil, United Kingdom
-
AstraZenecaParexelActive, not recruitingLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung CancerBelgium, United States, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Italy, Korea, Republic of, Brazil, Japan, Turkey, China, Malaysia, Germany, Spain, Australia, Hungary, Portugal, Switzerland, Israel, Philippines, Russian... and more